CME Group grants 2,864 shares to exec Sprague

CME Group officer Suzanne Sprague reported a new restricted stock grant and related share surrenders to cover tax withholding from vesting awards.

Rhea-AI Filing Summary

CME GROUP INC. (CME) reported that officer Suzanne Sprague, COO & Global Head of Clearing, received an award of 2,864 shares of Class A common stock on September 15, 2026 as restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

On September 15, 2026 and September 16, 2026, a total of 1,152 shares of Class A common stock were surrendered to CME Group Inc. to satisfy tax withholding obligations related to the vesting of previously granted restricted stock. These transactions were reported as direct ownership and were not made under a Rule 10b5-1 trading plan.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Sprague Suzanne

Role COO & Global Head of Clearing

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock Class A F2	308	$272.46	$84K
Grant/Award	Common Stock Class A F1	2,864	$275.09	$788K
Tax Withholding	Common Stock Class A F2	249	$275.09	$68K
Tax Withholding	Common Stock Class A F2	275	$275.09	$76K
Tax Withholding	Common Stock Class A F2	320	$275.09	$88K

Holdings After Transaction: Common Stock Class A — 15,548 shares (Direct)

Footnotes (2)

1. F1. Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.
2. F2. Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

Key Figures

Restricted stock granted: 2,864 shares Grant reference price: $275.09 per share Shares surrendered for tax withholding: 1,152 shares +2 more

5 metrics

Restricted stock granted 2,864 shares Award of Class A common stock on September 15, 2026

Grant reference price $275.09 per share Restricted stock award on September 15, 2026

Shares surrendered for tax withholding 1,152 shares Shares delivered or withheld to satisfy tax obligations on September 15–16, 2026

Tax withholding price on September 15, 2026 $275.09 per share Share surrender to cover tax withholding obligations

Tax withholding price on September 16, 2026 $272.46 per share Share surrender to cover tax withholding obligations

Key Terms

restricted stock, CME Group Omnibus Stock Plan, tax withholding obligations, continued service

4 terms

restricted stock financial

"Represents a grant of restricted stock under the CME Group Omnibus Stock Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

CME Group Omnibus Stock Plan financial

"Represents a grant of restricted stock under the CME Group Omnibus Stock Plan"

tax withholding obligations financial

"satisfy tax withholding obligations in connection with the vesting of restricted stock"

continued service financial

"vesting in four equal annual installments, subject to continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did CME (CME) officer Suzanne Sprague receive in this Form 4?

Suzanne Sprague received a grant of 2,864 shares of CME Group Class A common stock on September 15, 2026 as restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

Why were shares of CME (CME) surrendered by Suzanne Sprague in this Form 4?

A total of 1,152 shares of CME Group Class A common stock were surrendered to the issuer to satisfy tax withholding obligations arising from the vesting of restricted stock previously granted to Suzanne Sprague.

On what dates did the CME (CME) insider transactions by Suzanne Sprague occur?

The reported transactions occurred on September 15, 2026, when the restricted stock was granted and some shares were surrendered for taxes, and on September 16, 2026, when additional shares were surrendered to satisfy tax withholding obligations.

Were the CME (CME) insider transactions by Suzanne Sprague made under a Rule 10b5-1 plan?

No. The filing indicates that the transactions reported for Suzanne Sprague were not made pursuant to a Rule 10b5-1 trading plan, meaning no such pre-arranged trading instruction is affirmed for these events.

What type of security is involved in Suzanne Sprague’s CME (CME) Form 4 transactions?

All reported transactions involve Class A common stock of CME Group Inc., including restricted stock granted under the CME Group Omnibus Stock Plan and shares surrendered to the issuer for tax withholding on vesting.

What role does Suzanne Sprague hold at CME (CME) in this Form 4?

Suzanne Sprague is identified as an officer of CME Group Inc., holding the title COO & Global Head of Clearing, and the reported equity transactions relate to her compensation in the form of restricted stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:27 PM Accepted by SEC EDGAR 09/17/2026 - 04:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sprague Suzanne

(Last) (First) (Middle)

20 SOUTH WACKER DRIVE

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO & Global Head of Clearing

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	09/15/2026		A(1)		2,864	A	$275.09	16,700	D
Common Stock Class A	09/15/2026		F(2)		249	D	$275.09	16,451	D
Common Stock Class A	09/15/2026		F(2)		275	D	$275.09	16,176	D
Common Stock Class A	09/15/2026		F(2)		320	D	$275.09	15,856	D
Common Stock Class A	09/16/2026		F(2)		308	D	$272.46	15,548	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

2. Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

Remarks:

	/s/ Elizabeth Hensen, as Attorney-in-Fact for Suzanne Sprague	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)